(The author is a Reuters Breakingviews columnist. The opinions
expressed are his own.)
By Robert Cyran
NEW YORK, Jan 17 (Reuters Breakingviews) - Disclosing
its unsolicited $6.9 bln offer for NI ends a quiet eight-month
standoff. Going public forces the issue, but along with the
target’s strategic review also inflates the price. A bid battle
threatens the potential value of a deal and may inform takeover
tactics elsewhere.
Full view will be published shortly.
Follow @rob_cyran on Twitter
CONTEXT NEWS
Engineering services provider Emerson Electric said on Jan.
17 that it had offered to buy NI for $7.6 billion, including
debt. The $53 a share entreaty represents a 13% premium to where
NI’s stock closed on Jan. 13, the last day of trading before the
offer was made public.
Emerson said it had originally offered $48 per share in May
2022 but was rebuffed. Emerson added that NI, which makes
measurement and testing tools, has not “meaningfully engaged”
since its $53 offer in November.
NI, previously known as National Instruments, on Jan. 13
enacted a takeover defense tactic known as a poison pill. If a
buyer acquires more than 10% of NI’s stock, other shareholders
will have the right to buy an equal amount of shares as they
hold at a 50% discount. The plan expires on Jan. 12, 2024.
Emerson has purchased 2.3 million shares in NI, or about
1.8% of the amount outstanding.
(Editing by Jeffrey Goldfarb and Amanda Gomez)
((For previous columns by the author, Reuters customers can
click on CYRAN/
SIGN UP FOR BREAKINGVIEWS EMAIL ALERTS https://bit.ly/BVsubscribe
| robert.cyran@thomsonreuters.com; Reuters Messaging:
robert.cyran.thomsonreuters.com@reuters.net))